CJC-1295 + Ipamorelin 5 mg + 5 mgPack de 10 frascos6 em stockPoupe 22%
Em destaquepeptideintermediate6 em stock

CJC-1295 + Ipamorelin 5 mg + 5 mg

Combinação clássica de GHRH + mimético da grelina

CJC-1295 and Ipamorelin research stack, Australian-shipped. Lab-verified to ≥99% purity.

Dose
5mg + 5mg / frasco
Forma
Pó liofilizado
Pack
Pack de 10 frascos

Apenas para uso em investigação. Este composto é vendido estritamente para investigação in vitro e fins laboratoriais e não se destina ao consumo humano nem a uso terapêutico. Ao comprar, confirma que é um investigador qualificado e aceita o nosso aviso legal completo.

186 € EUR
Poupe 22%
Pack de 10 frascos
Antes 238 € EUR
Vendido em pack de 10 frascos

Restam apenas 6 packs

🧪Verificado em laboratório
✓Analisado por terceiros
⚡Envio mundial rápido
🔒Pagamento seguro com cartão
Descrição

Frasco de investigação combinado que emparelha o análogo de GHRH CJC-1295 com o mimético seletivo da grelina Ipamorelin. A combinação de secretagogos de GH de duplo mecanismo mais estudada na investigação de péptidos.

CJC-1295 and Ipamorelin are a long-standing pair in growth-hormone secretagogue research. CJC-1295 is a 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH); Ipamorelin is a selective ghrelin receptor agonist (a 'GHS' or growth-hormone secretagogue). The two compounds act on different receptors but converge on the somatotrophs of the anterior pituitary, where they amplify pulsatile growth-hormone release in pre-clinical models.

Quantum Labs supplies the pair as a pre-portioned research stack — two lyophilised vials shipped together, each HPLC-verified to ≥99% purity. Australian-shipped from local stock; supplied for laboratory research use only.

Mecanismo

CJC-1295 apoia a sinalização basal do recetor de GHRH, enquanto Ipamorelin impulsiona pulsos seletivos do recetor da grelina. A investigação sugere padrões sinérgicos e naturalistas de libertação de GH em sujeitos de estudo.

Relatório laboratorial

Verificado por HPLC face a uma especificação de pureza ≥99 %. Testado de forma independente por laboratórios terceiros acreditados.

CJC-1295: DAC vs no-DAC

CJC-1295 exists in two research forms: with Drug Affinity Complex (DAC) and without. The DAC variant binds albumin in plasma, extending the half-life from minutes to days. Research designs targeting acute pulsatile GH release typically use the no-DAC form (modified GRF 1-29); studies modelling sustained GH elevation use the DAC variant. Our supply is the no-DAC research-grade form unless otherwise specified.

FAQ para investigadores

CJC-1295 + Ipamorelin — perguntas frequentes

What is the CJC-1295 + Ipamorelin stack?

It is a research pairing of two growth-hormone secretagogues: CJC-1295 (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist). The two compounds act on different receptors but converge on stimulating pulsatile growth-hormone release in pre-clinical models.

How does CJC-1295 differ from Ipamorelin?

CJC-1295 mimics growth-hormone-releasing hormone (GHRH), binding the GHRH receptor on pituitary somatotrophs. Ipamorelin mimics ghrelin, binding the growth-hormone secretagogue receptor (GHSR-1a). The two pathways are independent but synergistic — combining them produces a larger pulsatile GH response in research models than either compound alone.

Is CJC-1295 + Ipamorelin legal in Australia?

Both compounds are restricted for human therapeutic supply in Australia and remain available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies the stack for research use only.

What does selective mean for Ipamorelin?

Ipamorelin is described as a selective ghrelin agonist because it activates the GH-release pathway with minimal effect on cortisol, prolactin, or aldosterone — distinguishing it from earlier-generation GHS molecules. This selectivity has made it a preferred research tool for isolating GH-specific effects.

What is the typical CJC-1295 + Ipamorelin research dosage?

Published research protocols have used wide dose ranges depending on the model and species. Human dosing is not established. Researchers should consult primary literature for protocol-specific guidance.

Are CJC-1295 and Ipamorelin used together?

Yes — combined-administration research is common precisely because the two compounds act on independent receptors and produce a synergistic GH-release response. The combination is a standard tool in growth-hormone secretagogue research.

Leituras adicionais

Guias relacionados com CJC-1295 + Ipamorelin

Compostos relacionados

Os investigadores também exploram